Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints |
| |
Affiliation: | 1. Department of Obstet. Gynecol., University of Vienna, Spitalgasse 23, 1090 Vienna, Austria;2. A.Ö. KH Elisabethinen, Fadingerstr. 1, 4010 Linz, Austria;3. Menox Salzburg, Nonntaler Hauptstr. 1, 5020 Salzburg, Austria;4. Dept. Gynecol. Obstet., University of Graz, Auenbruggerplatz 14, 8036 Graz, Austria;5. SMZ-Ost, Langobardenstr. 122, 1220 Vienna, Austria;1. Department of Dermatology, Pius Hospital de Valls, Tarragona, Spain;2. University Hospital of Fuenlabrada, Madrid, Spain;3. Eldine Pathology Laboratory, Tarragona, Spain;1. Department of Ultrasound, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China;2. Neuroradiology Division, Department of Radiology, University of Virginia, Charlottesville, VA, USA;3. Department of Radiation Oncology, University of Virginia, Charlottesville, VA, USA;4. ESPCI ParisTech, PSL Research University, Institut Langevin, Paris, France;5. CNRS, Institut Langevin, Paris, France;6. INSERM, Institut Langevin, Paris, France;7. Department of Anesthesiology, Shanghai Sixth Hospital, Shanghai Jiaotong University, Shanghai, China;11. Departments of Neuroscience and Neurologic Surgery, University of Virginia, Charlottesville, VA, USA;12. Department of Radiology, University of Virginia, Charlottesville, VA, USA;8. Image Guided Therapy, Pessac, France;1. Department of Radiation Oncology, University of Texas Medical Branch, Galveston, TX;2. Department of Radiation Oncology, The Methodist Hospital, Cancer Center and Research Institute, Houston, TX;3. Department of Surgery, The Methodist Hospital, Houston, TX;1. Department of Clinical and Experimental Medicine, Research Unit of Histology & Embryology, University of Florence, Viale Pieraccini, 6, 50139 Firenze, Italy;2. Department of Chemistry “Ugo Schiff”, University of Florence, Via della Lastruccia, 3, 50019 Sesto Fiorentino, Firenze, Italy |
| |
Abstract: | Objective: Tibolone has been shown to alleviate climacteric symptoms. This study was designed to compare the effect of tibolone (Livial®, 2.5 mg daily) on different climacteric complaints and its impact on the endometrium, determined by vaginal ultrasound, with that of conjugated estrogens (Premarin®, 0.625 mg daily) continuously for 6 months in combination with the progestogen medrogestone (Colpron®, 2 × 5 mg daily for 12 days each month). Methods: One hundred and twenty-nine postmenopausal women were recruited and the severity of climacteric symptoms as well as endometrial thickness were recorded at the pre-trial examination and after 1, 3, and 6 months. Results: With the exception of vertigo, mood depression, mood disorder, loss of libido, and dryness of skin, where tibolone was found to be more effective than conjugated estrogens/medrogestone, climacteric symptoms improved significantly in both groups over the 6-month study period. Endometrial thickness did not increase significantly in the tibolone group, whereas in the conjugated estrogens/medrogestone group there was a highly significant increase after 1 month and still a trend towards significance after 6 months. Recurrence of vaginal bleeding occurred significantly less frequently in the tibolone group than in the comparison group. Conclusion: Tibolone seems to offer a complete treatment of the climacteric complaints whilst avoiding some of the problems associated with classical hormone replacement therapy. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|